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Abstract
There is considerable evidence that the translation rate of major basic science promises to clinical
applications has been inefficient and disappointing. The deficiencies of translational science have
often been proposed as an explanation for this failure. An alternative explanation is that until
recently basic science advances have made oversimplified assumptions that have not matched the
true etiological complexity of most common diseases; while clinical science has suffered from poor
research practices, overt biases and conflicts of interest. The advent of molecular medicine and the
recasting of clinical science along the principles of evidence-based medicine provide a better
environment where translational research may now materialize its goals. At the same time, priority
issues need to be addressed in order to exploit the new opportunities. Translational research
should focus on diseases with global impact, if true progress is to be made against human suffering.
The health outcomes of interest for translational efforts need to be carefully defined and a balance
must be struck between the subjective needs of healthcare consumers and objective health
outcomes. Development of more simple, practical and safer interventions may be as important a
target for translational research as the development of cures for diseases where no effective
interventions are available at all. Moreover, while the role of the industry is catalytic in translating
research advances to licensed interventions, academic independence needs to be sustained and
strengthened at a global level. Conflicts of interest may stifle translational research efforts
internationally. The profit motive is unlikely to be sufficient alone to advance biomedical research
towards genuine progress.
Introduction
The status of translational research has drawn increasing
attention recently in top biomedical journals [1-5] and in
the policy making of the NIH, as reflected also in the NIH
Roadmap [6]. Translational medicine encompasses all the
disciplines that intervene in moving scientific progress
from the bench to the bedside and in conveying stimulat-
ing information from the bedside back to the bench [5].
While basic sciences are conceived as having made amaz-
ing leaps forward, this progress has not resulted in many
major cures [7]. At the other end, clinicians are considered
too unfamiliar with the capacities of modern science to
bring fruitful questions to the attention of basic scientists
[5]. Nevertheless, recent evolutions in basic and clinical
science have created a new window of opportunity for the
growth of translational medicine. The aim of this com-
mentary is to discuss why translational efforts might have
failed to-date, how this new opportunity may be best
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overcome.
Inefficient translation rates
My team recently examined the rate of translation of
promising basic research findings to clinical applications
[8]. We screened reports published between 1979–1983
in 6 top basic science journals (Science, Nature, Cell, Jour-
nal of Biological Chemistry, Journal of Experimental Med-
icine, and Journal of Clinical Investigation). We found
101 articles that clearly made a promise for a major clini-
cal application of their findings. Two decades later, only 5
of these promises were in licensed clinical use and only
one of them had a major impact on current medical prac-
tice. Three quarters of the basic science promises had not
yet been tested in a randomized trial. The strongest predic-
tor of moving to randomized experimentation was indus-
try involvement in the original basic science publication.
In the absence of such involvement, scientists could not
see their findings materialize (figure 1). Since the ana-
lyzed publications represented very early stage basic
research, this suggests that the industry is willing to
develop mostly research paths where it has been involved
from the very early basic science start, rather than pick up
the lines of basic research that have been developed inde-
pendently, often with highly competitive government
support.
Many investigators might interpret these results as evi-
dence that translational medicine has failed to match
basic science advances. Clinical research would also be
absolved for this failure, since clinical research methods
(clinical trials in particular) are considered as being well
established for many decades. The first randomized clini-
cal trial was published 56 years ago. However, a different
interpretation is possible: perhaps basic science had often
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clinical science had often been unfocused, biased, of poor
scientific standards, and driven by priorities not congru-
ent with the true health needs of humankind.
Basic sciences: maturing in complexity
Basic science advances in the last few years have indicated
that most common diseases entail extremely complex pat-
terns of pathogenesis, involving the regulation of dozens
and hundreds of genes and their protein products. In the
light of advances in genomics, proteomics, and bioinfor-
matics, basic science of the 1980s and 1990s where single
or few pathways were investigated would currently seem
naïve at best. We don't know yet whether the molecular
medicine of the early 21st century may seem equally over-
simplified even within a decade or two. The complex new
patterns of disease etiology and regulation still pose con-
siderable problems of validation and testing of generaliz-
ability [9,10]. The role of environmental parameters and
their interactions at the molecular level with intrinsic fac-
tors is yet largely unknown. These interactions may prove
to be even more formidable at disentangling. It is proba-
bly premature to believe that all human diseases will be
erased by the year 2050, as was claimed recently [11]. The
intractability of several chronic diseases, the unpredicta-
ble emergence of new diseases such as AIDS, SARS, and
mad cow disease and the equally unpredictable re-emer-
gence of old diseases such as tuberculosis makes such a
target an utopia. Nevertheless, provided that we approxi-
mate the depth of the complexity of the molecular issues
involved, translational medicine may have indeed a more
solid starting point now in its efforts.
Clinical sciences: maturing in evidence base
Clinical research has been even more revolutionized in
the last decade, in particular with the advent of evidence-
based medicine. It is now acknowledged that a large cor-
pus of clinical information that has haunted the top med-
ical textbooks and experts' opinions was wrong, outdated,
and/or dangerous for human health [12]. Evidence-based
medicine has placed emphasis on robust scientific princi-
ples, the dissection of strengths and limitations of various
clinical research designs, and the identification of bias in
medical research [13]. We are now aware that serious
errors may underpin much of clinical research, and even
randomized trials may succumb to biases [14]. Moreover,
clinical scientists have now tried to systematize their
knowledge base. Efforts such as the Cochrane Collabora-
tion [15,16], an international coalition that aims to gen-
erate systematic reviews on all aspects of health care, has
been hailed as equivalent in scope to the Human Genome
Project [17]. Such systematic efforts can tell us reliably for
each disease and condition whether we have enough evi-
dence for its effective management, and whether this evi-
dence is biased or not. Furthermore, rigorous approaches
have been recently developed to quantify the burden of
disease for various conditions [18]. It is thus becoming
evident that for several trivial issues, there is often a waste
variety of expensive treatments, while for many serious
conditions there is no effective intervention at all and lit-
tle research is targeted at them [19,20].
Priorities and cross-links between diseases
With genuine progress in the basic and clinical sciences,
translational efforts have a better chance of being success-
ful. Even under these circumstances though, the question
remains on who will do this research and where it will be
done. A very large portion of all current research is done
in the USA. Scientific papers with US authorship attract
approximately half of all citations in the Web of Science
(over 30 million citations in the last decade alone, fol-
lowed by England with less than 6 million) [21]. A hand-
ful of developed countries make up another 40–45% of
the total citations. NIH is by far the greatest governmental
funding body for biomedical research globally. However
the USA, with 4% of the total global population, carry a
negligible portion of the global burden of disease [20].
Several health targets that may seem important to the US
population may be of second-rate importance for global
health. Hopefully, different diseases that have been tradi-
tionally categorized under different organ systems and
under different NIH institutes may share common patho-
genesis principles and may warrant similar approaches to
their understanding and management. The recognition of
the importance of these cross-links in the NIH policy [6]
creates hope for "collateral" gains in medical progress
against diverse diseases. Broad-spectrum advances may be
exploited for the opportunistic targeting of diseases
besides the original targets that concern affluent societies.
Of course, the eventual translation of basic science leads
will probably continue to be disease oriented and aimed
at "the benefit of our people", as the NIH Roadmap edito-
rial in Science states [6]. However, "our people" in fact is
"humanity at large". It may be argued that the basic sci-
ence investment of the US is probably one of the most
prominent components of foreign and domestic aid that
the leading country can offer to the rest of the world.
However, like much other aid that is wasted, it is unclear
whether that research investment is used efficiently for the
rest of the world.
Clarifying health outcomes for translational 
efforts
Many clinicians, in particular those working in tertiary
care, feel increasingly that medicine in the USA and other
developed countries has lost much of its focus and is
mostly preoccupied with highly expensive trivia of tan-
gential relationship with the true quality and dignity of
human life. What do we really wish to achieve with
healthcare? This is a prime question to answer, to decidePage 3 of 6
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aging that the NIH Roadmap discusses, under transla-
tional research issues, the assessment of clinical outcomes
and the need to develop more sensitive and well-validated
tools to improve outcome measurements [6]. It is also
anticipated that research should be directed to therapies
that would be most highly valued by patients [6]. The
emancipation of patients from paternalistic physician
control in valuing health preferences is important. How-
ever, we also have to strike a balance between subjective
needs and objective facts. For example, it is pitiful that for
many treatments, the collection of information has tradi-
tionally focused more on efficacy than on toxicity. For dis-
eases where treatments are already available, a major role
for translational efforts may be to generate safer interven-
tions. However, how is this to be achieved when objective
data on adverse events are not even properly reported in
the scientific literature [22]? Even when collected, such
data are often rapidly lost and unavailable for further
comparative study [23].
Moreover, subjective needs are important, but their sub-
jectivity has to be reckoned seriously. In health interviews
in Ghana, a large proportion of serious medical problems
that were subsequently obvious upon physical examina-
tion were not considered enough of a problem to even
mention to interviewers [24]. Conversely, in affluent soci-
eties marketing and advertising forces may manipulate
and generate trivial subjective needs. This may be
enhanced through up-scaled direct-to-consumer advertis-
ing [25]. Subjective needs pertain not only to treatments,
but also to other health technology advertised as essential
for prevention or self-knowledge of health risks, e.g. pop-
ulation genomic testing [26]. New health products in such
societies may have weird elasticity features. For most
goods, more expensive pricing leads to lower consump-
tion. In modern medicine, this is often reversed. The more
expensive or convoluted a product is, the more aggres-
sively it may be sought, even when the benefit is question-
able. For example, the introduction of new, expensive
broad-spectrum drugs has led to increasing expenses for
out-of-hospital antibiotics, as these expensive agents are
over-prescribed despite lacking genuine indications [27].
Developing practical interventions
Another common misconception about translational
medicine is that it always has to deal with diseases that are
not only complex, but also represent key preoccupations
of cutting-edge basic research. Many diseases are very
important in terms of costing human lives and quality of
life, but nevertheless they have not been prime targets for
high-profile basic science [28]. Many patients suffer
worldwide from injuries, war, malnutrition, and
untreated infectious diseases. For many of these
conditions, high tech molecular science may not be the
prime approach to address them. Still, translational
research is needed and should focus on finding practical
solutions for their prevention and treatment. Even for dis-
eases where currently treatment is available, e.g. HIV/
AIDS, such treatment is of no use, if it cannot reach effec-
tively even 5% of the patients who need it [29]. Transla-
tional research has a prime role here. While such "access"
problems usually have their roots in political and finan-
cial setbacks, it may be erroneous to wait for these defi-
ciencies to be corrected worldwide. Translational efforts
could aim at developing treatments and modes of delivery
thereof that would make wide implementation feasible,
even if the political and financial circumstances were far
Research players at large-scale: research budget of the Euro-p an Commission (6th Framewo k Programme [FP]) and the NIH s co pared with the revenue of large pharmac utical companiesFigure 2
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NIH as compared with the revenue of large pharmaceutical 
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actually be an efficient strategy even for correcting finan-
cial deficiencies.
Motives, conflicts and biases
Translational research itself is increasingly prioritized by
financial motives. The private sector has become more
important than government in biomedicine (figure 2). A
large component of translational activities are conducted
for the industry, either by the industry itself or by
academia and other research centers. The industry also
funnels a lot of its funding to non-academic contract-
research organizations who have emerged as competitors
to academic centers. Relationships between the industry
and academia are continuously reappraised, but the asso-
ciation is certainly not a completely smooth one [30-32].
Conflicts of interest, demise of scientific independence,
and the subordination of scientific quality to profit seek-
ing are the main problems that may arise in this tenuous
partnership.
On the one hand, it should be clearly acknowledged that
the profit motive has been the driving force behind many
important discoveries in healthcare. Under healthy scien-
tific and regulatory environments, relationships with the
industry can be enhancing to the academic and scientific
mission and can yield valuable products for developed
countries. For less developed countries, the profit motive
needs to be modulated to achieve some benefits [33].
Conversely, the industry can have crushing effects on
investigators even in strong academic institutions such as
well-publicized cases from UCSF and the University of
Toronto prove [34,35]. The average European academic
institution, let alone institutions in the developing world,
may not be able to withstand corporate pressure. Tenuous
funding from central sources and poor and non-transpar-
ent peer-review systems, along with variable degrees of
academic and administrative corruption, create a setting
that leaves little room for genuine resistance against
industry advances. Burdensome administrative directives
such as the recently proposed European Directive on Clin-
ical Trials may inadvertently inhibit clinical research that
is independent of the industry. Already the academic
establishment at many countries is actively supported by
the industry as a peculiar star system that primarily adver-
tises and promotes its products. Tons of low-quality scien-
tific meetings publicize pseudo-translational research
according to industrial priorities.
Conflicts of interest are often difficult to probe and under-
reported even in the US [36]. It is thus not surprising that
in economical analyses in oncology, only 5% of com-
pany-sponsored studies have found that interventions are
not cost-effective, as compared with 38% of not-for-profit
sponsored studies [37]. When it comes to the countries
with less strong research tradition, the massacre of aca-
demic freedom may be unconditional. Recently, a profes-
sor of pharmacology from a Balkan country visited my
university. I was surprised to find out that his team had
conducted over a hundred phase I studies under the aus-
pices of the industry. The results are rarely published of
course, unless the sponsors wish so.
Lost "negative" science
The delay in the publication or even lack of publication of
"negative" results has been shown even for NIH-spon-
sored, large, efficacy randomized trials [38]. Publication
bias against "negative" results may be the rule rather than
the exception worldwide when it comes to phase I experi-
mentation [39] or basic science efforts. As regulatory rules
for translational and clinical research become stricter, but
not necessarily better, in a few "advanced" countries,
much translational research may be conducted at an
opportunity cost in non-transparent settings. The picture
emerging from the world scientific literature may be a
highly distorted one.
The availability of electronic publication should help the
unimpeded dissemination of "negative" research find-
ings, since space limitation is no longer an issue as in
printed journals. Moreover, there is a need to reverse the
mentality that "negative" findings represent worse
research than "positive" findings. Research effort should
be respected on the basis of the rigorousness of its design,
hypotheses, and execution, and not on the basis of its
results. The nature of the results will unavoidably be used
to guide the further applicability of research, but it should
not be used to judge also its scientific merit. Lack of dis-
semination of "negative" findings may also lead to a waste
of investing resources on researching again and again
pathways that would otherwise have been known to be
unproductive, if the "negative" results of prior investiga-
tors had become widely available.
Conclusions
As basic and clinical sciences mature, translational
research has a chance of making an important difference
for human health. However, priorities need to be selected
with broad horizons in mind. A global perspective should
be assumed not only in priority setting, but also on the
conduct of research. Universal guidelines that are consist-
ent with the realities of the 21st century biotechnology
industry and academic science should be adopted. The
rules should be clear and they should reward creativity,
maximize transparency, and exploit local strengths, not
stifle progress with irrelevant administrative burdens. The
inability to create a truly international scientific society
with high standards, transparent processes, and academic
independence may create a poorer world for all of us.Page 5 of 6
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